Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) Income towards Parent Company (2019 - 2025)

Keros Therapeutics filings provide 7 years of Income towards Parent Company readings, the most recent being -$23.5 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company rose 49.03% to -$23.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $87.0 million, a 146.44% increase, with the full-year FY2025 number at $87.0 million, up 146.44% from a year prior.
  • Income towards Parent Company hit -$23.5 million in Q4 2025 for Keros Therapeutics, down from -$7.3 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $148.5 million in Q1 2025 to a low of -$53.0 million in Q3 2024.
  • Median Income towards Parent Company over the past 5 years was -$28.5 million (2022), compared with a mean of -$21.7 million.
  • Biggest five-year swings in Income towards Parent Company: plummeted 328.21% in 2022 and later soared 444.32% in 2025.
  • Keros Therapeutics' Income towards Parent Company stood at -$6.9 million in 2021, then plummeted by 328.21% to -$29.7 million in 2022, then crashed by 56.32% to -$46.5 million in 2023, then grew by 0.92% to -$46.0 million in 2024, then surged by 49.03% to -$23.5 million in 2025.
  • The last three reported values for Income towards Parent Company were -$23.5 million (Q4 2025), -$7.3 million (Q3 2025), and -$30.7 million (Q2 2025) per Business Quant data.